Epirubicin

Generic Name: Epirubicin

Brand Names: Ellence, Pharmorubicin PFS

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₉NO_₁₁

CAS Number: 56420-45-2

Unique Ingredient Identifier: 3Z8479ZZ5X

Background: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.

Indication: For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

Associated Conditions: Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder

Associated Therapies: -

Clinical Trials

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: RAD001

First Posted Date: 2007-07-11

Last Posted Date: 2016-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT00499603

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Trastuzumab
Drug: Bevacizumab

First Posted Date: 2007-04-23

Last Posted Date: 2021-10-25

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 105

Registration Number: NCT00464646

Locations: 🇺🇸
CCOP, Cancer Research for the Ozarks, Springfield, Missouri, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University Hospital and Medical Center - SUNY, Stony Brook, New York, United States

and more 33 locations

A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.

Phase 2

Completed

Conditions: Gastric Cancer

Interventions: Drug: Cisplatin
Drug: Epirubicin
Drug: Docetaxel
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2007-04-02

Last Posted Date: 2016-09-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 158

Registration Number: NCT00454636

Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

Phase 2

Conditions: Oesophagogastric Cancer

Interventions: Biological: bevacizumab
Drug: capecitabine
Drug: Epirubicin
Drug: cisplatin
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: conventional surgery
Drug: Lapatinib

First Posted Date: 2007-03-22

Last Posted Date: 2016-12-01

Lead Sponsor: Professor David Cunningham

Target Recruit Count: 1103

Registration Number: NCT00450203

Locations: 🇬🇧
Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
🇬🇧
Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom
🇬🇧
Cumberland Infirmary, Carlisle, England, United Kingdom

and more 38 locations

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Exemestane
Drug: Cyclophosphamide
Drug: Goserelin
Drug: Docetaxel
Drug: Carboplatin

First Posted Date: 2007-02-07

Last Posted Date: 2023-04-03

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 189

Registration Number: NCT00432172

Locations: 🇪🇸
Onkologikoa, Donostia, Gipuzkoa, Spain
🇪🇸
Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain
🇪🇸
Centro Oncológico Regional de Galicia, A Coruña, Spain

and more 9 locations

Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Pegylated liposomal doxorubicin (Caelyx)

First Posted Date: 2007-02-06

Last Posted Date: 2013-02-13

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 100

Registration Number: NCT00431795

Locations: 🇬🇷
"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Piraeus, Greece
🇬🇷
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷
State General Hospital of Larissa, Dep of Medical Oncology, Larissa, Greece

and more 7 locations

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: 5-fluoruracil
Drug: Granulocyte-colony stimulating growth factor

First Posted Date: 2007-02-05

Last Posted Date: 2008-01-21

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 478

Registration Number: NCT00431080

Locations: 🇬🇷
"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Piraeus, Greece
🇬🇷
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece

and more 7 locations

Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Capecitabine
Drug: Epirubicin

First Posted Date: 2007-02-01

Last Posted Date: 2009-05-29

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 272

Registration Number: NCT00429871

Locations: 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷
Air Forces Military Hospital of Athens, Athens, Greece
🇬🇷
401 Military Hospital of Athens, Athens, Greece

and more 7 locations

Breast Cancer Treated by Neoadjuvant Chemotherapy

Phase 2

Completed

Conditions: Individualized Chemotherapy

Interventions: Drug: Taxotere
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2007-01-23

Last Posted Date: 2014-10-01

Lead Sponsor: Centre Jean Perrin

Target Recruit Count: 264

Registration Number: NCT00425516

Locations: 🇫🇷
Hospital center, Brive La Gaillarde, France
🇫🇷
Centre Jean Perrin, Clermont Ferrand, France
🇫🇷
Edouard Herriot University Hospital, Lyon, France

and more 3 locations

Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Docetaxel

First Posted Date: 2007-01-19

Last Posted Date: 2015-05-20

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 658

Registration Number: NCT00424606

Locations: 🇬🇷
University Hospital of Heraklion, Heraklion, Crete, Greece
🇬🇷
University Hospital of Alexandroupolis Dept. of Medical Oncology, Alexandroupolis, Greece
🇬🇷
"Laikon" General Hospital, Athens, Greece

and more 9 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy